An Open-label Study of Azetukalner in Bipolar I or II Depression (X-CEED-OLE)
Status:
ENROLLING_BY_INVITATION
Trial end date:
2029-08-01
Target enrollment:
Participant gender:
Summary
X-CEED-OLE is a Phase 3, multicenter, open-label study to evaluate the long-term safety, tolerability, and efficacy of azetukalner in adult participants who successfully completed an antecendent Phase 3 azetukalner bipolar depression study.